By coupling individual phosphoproteomic data with kinase-substrate relationships, activated kinases in post-treatment tumors in comparison with pre-treatment tumors with regards to HER2-positive gastric cancer, and those in tumors in comparison with non-tumor adjacent tissues could be inferred in a personalized manner. The gene discussed is ERBB2; the disease is neoplasm.